Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease.

Paula McClean, Victor Gault, Patrick Harriott, Christian Holscher

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

Type 2 diabetes has been identified as a risk factor for patients with Alzheimer's disease. Insulin signalling is often impaired in Alzheimer's disease, contributing to the neurodegenerative process. One potential strategy to help prevent this is the normalisation of insulin signalling in the brain. Therefore, the present study was designed to test the effects of novel enzyme-resistant analogues of the insulin-releasing incretin hormone, glucagon-like peptide 1 (GLP-1). The effects of Liraglutide (Victoza) and other novel GLP-1 analogues were tested on synaptic plasticity (LTP) in area CA1 of the hippocampus. At a dose of 15nmol in 5microl i.c.v., Liraglutide (P
Original languageEnglish
Pages (from-to)158-162
JournalEuropean Journal of Pharmacology
Volume630
Issue number1-3
Early online date24 Dec 2009
DOIs
Publication statusPublished - 25 Mar 2010

Fingerprint Dive into the research topics of 'Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease.'. Together they form a unique fingerprint.

  • Cite this